Presentation of Probi’s Q1 report 2017

Probi’s report for the first quarter 2017 will be published on Thursday, 4 May at 8.00 a.m.

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Peter Nählstedt and CFO Jörn Andreas will present and comment on the report. The presentation and presentation material can be obtained via www.probi.se or https://tv.streamfabriken.com/probi-q1-2017  

The presentation can also be followed via a telephone conference on the following telephone number:

Sweden: +46 8 56 64 26 92
UK: +44 20 30 08 98 04
US: +1 85 57 53 22 36

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the addresses given above following thepresentation.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: peter.nahlstedt@probi.com
Jörn Andreas, CFO, Probi, tel +46 46 286 89 41, e-mail: jorn.andreas@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2016, Probi had net sales of MSEK 444. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.se.

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links